TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4902196
Drug: Protein-free liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-free liver extract (Ripason) administered both orally and intramuscularly
Study: 24937390
Drug: Double-modality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-modality therapy (DMT) - cryotherapy and 15% methyl salicylate phonophoresis
Study: 24937390
Drug: Double-modality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-modality therapy (DMT)
Study: 21689019
Drug: Formoterol by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol by pressurized metered-dose inhaler (pMDI) 12 μg b.i.d.
Study: 21689019
Drug: Formoterol by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol by dry powder inhaler (DPI) 12 μg b.i.d.
Study: 18687132
Drug: Intravenous antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antioxidant supplements (selenium 270 microg, zinc 30 mg, vitamin C 1.1 g, and vitamin B1 100 mg) for 5 days with a double-loading dose on days 1 and 2
Study: 18687132
Drug: Intravenous antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antioxidant supplements
Study: 12631424
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan orally
Study: 9850897
Drug: 3 drops
Normalized name: UpSpring WellBaby DHA + Vitamin D3 Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops of lidocaine 4% plus intracameral injection of 0.1 mL lidocaine 1%
Study: 2531908
Drug: Polyvalent melanoma
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent melanoma cell vaccine alone
Study: 2531908
Drug: Polyvalent melanoma
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent melanoma cell vaccine with low-dose cyclophosphamide
Study: 2531908
Drug: Other immunomodulators
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other immunomodulators (alone or in combination with lower doses of cyclophosphamide)
Study: 11711455
Drug: Intervention trials
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention trials on treatment of acute myocardial infarction
Study: 31075706
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), 12 sessions
Study: 29438425
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid ointment
Study: 11782569
Drug: Cisapride, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 20 mg b.i.d., during 4 weeks
Study: 10095800
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin daily for 6 weeks, followed by 80 mg atorvastatin for another 6 weeks
Study: 10095800
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin alone
Study: 10095800
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin with 8-12 g colestyramin
Study: 10095800
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin with 1800 mg nicotinic acid
Study: 29500292
Drug: Intravenous elamipretide
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous elamipretide (0.25 mg/kg/h)
Study: 29500292
Drug: Intravenous elamipretide
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous elamipretide (highest dose)
Study: 21676990
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 10 weeks
Study: 21676990
Drug: Clinical monitoring
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical monitoring (no new treatment)
Study: 17579653
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) group (n=38)
Study: 12824815
Drug: 21‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg nicotine patch
Study: 10873077
Drug: i.p. recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.p. recombinant IFN-gamma (rIFN-gamma) and higher rIL-2 dosing (group A)
Study: 10873077
Drug: i.p. recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.p. recombinant IFN-gamma (rIFN-gamma) and lower rIL-2 dosing (group B)
Study: 8879704
Drug: Sodium clodronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium clodronate, total daily dose of 1600‐3200 mg
Study: 6229564
Drug: Trazodone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (300 mg mean maintenance dosage, range 200-350 mg)
Study: 6229564
Drug: Imipramine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (160 mg mean maintenance dosage, range 150-175 mg)
Study: 31107560
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lidocaine‐and‐prilocaine (LP) cream for 120 minutes
Study: 26848561
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg twice daily added to subcutaneous interferon β‐1a therapy
Study: 26848561
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to subcutaneous interferon β‐1a therapy
Study: 18974025
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 7 days (Group A)
Study: 18974025
Drug: Esomeprazole 20mg
Normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 10 days (Group B)
Study: 18974025
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg b.d. for 7 days (Group C)
Study: 18974025
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg b.d. for 10 days (Group D)
Study: 18974025
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days treatment (Groups A and C)
Study: 18974025
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days treatment (Groups B and D)
Study: 18974025
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily levofloxacin (Group B)
Study: 18974025
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily levofloxacin (Groups C and D)
Study: 15854188
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg as needed
Study: 11980623
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g testosterone gel daily for 10 days
Study: 11980623
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g testosterone gel daily for 10 days
Study: 11980623
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g testosterone gel with washing off after 10 min
Study: 2032716
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b subcutaneously (s.c.) 5 x 10(6) IU three times weekly for four weeks
Study: 7072623
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg riboflavin daily for 12 weeks
Study: 24958479
Drug: Adalimumab (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (subcutaneous, every 2 weeks for 12 weeks)
Study: 24958479
Drug: Placebo (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous, every 2 weeks for 12 weeks)
Study: 22042703
Drug: Dexamethasone 0.3
Normalized name: dexamethasone 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.3 mg·kg(‐1)
Study: 15695985
Drug: Oral mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mifepristone (200 mg, administered orally)
Study: 15695985
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (infusion)
Study: 8507025
Drug: 4.4 mL
Normalized name: APONVIE 32 MG in 4.4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 mL of 2% lidocaine with 1:80,000 epinephrine
Study: 8507025
Drug: 4.4 mL
Normalized name: APONVIE 32 MG in 4.4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 mL of 3% prilocaine with 0.03 IU/mL felypressin
Study: 3908331
Drug: Acebutolol (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (100-400 mg)
Study: 3908331
Drug: Propranolol (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-160 mg)
Study: 3543146
Drug: Intravenous chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chloroquine
Study: 3543146
Drug: Subcutaneous chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous chloroquine
Study: 27097693
Drug: Oral chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloroquine
Study: 20557362
Drug: PPI-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based triple therapy plus S. boulardii for 4 weeks
Study: 20557362
Drug: PPI-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based triple therapy plus S. boulardii and DA-9601 for 4 weeks
Study: 20557362
Drug: PPI-based 7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based 7-day triple therapy
Study: 16151466
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD-AraC) alone (2 x 10 mg/m2/day subcutaneously days 1-14)
Study: 16151466
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD-AraC) plus granulocyte/macrophage colony stimulating factor (rhGM-CSF) (150 microg/day s.c. from day 8 to 21)
Study: 16151466
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD-AraC) plus Interleukin-3 (IL-3) (150 microg/day s.c. from day 8 to 21)
Study: 16151466
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD-AraC) with GM-CSF or IL-3
Study: 9370836
Drug: Morphine patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient-controlled analgesia
Study: 1606996
Drug: Oxazepam 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 7.5 mg
Study: 1606996
Drug: Oxazepam 35
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam 35 mg
Study: 1606996
Drug: Oxazepam 45
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam 45 mg
Study: 1606996
Drug: Oxazepam 50
Normalized name: oxazepam 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 50 mg
Study: 3896566
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily beclomethasone dipropionate (BDP)
Study: 3896566
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily beclomethasone dipropionate (BDP)
Study: 30796818
Drug: Ad26.ZEBOV dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV dose 1
Study: 29473247
Drug: D-methionine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-methionine (100 mg/kg p.o. b.i.d.)
Study: 24249842
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise programme including group exercise training twice a week and daily walks
Study: 22067197
Drug: Food intake
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food intake (standard breakfast 30 to 10 minutes prior to dosing)
Study: 22067197
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (400 mg of moxifloxacin)
Study: 16105374
Drug: Enhanced occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced occupational therapy support intervention
Study: 10902449
Drug: 5% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% prilocaine (1 mg/kg, n = 27)
Study: 10902449
Drug: 2% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mepivacaine (0.8 mg/kg, n = 30)
Study: 9398880
Drug: LAC1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC1 (1 week of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Study: 9398880
Drug: LAC2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC2 (2 weeks of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Study: 7979622
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times a day)
Study: 3891188
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg a day)
Study: 28343051
Drug: Cariprazine 3–6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3–6 mg/d
Study: 28343051
Drug: Cariprazine 9–12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 9–12 mg/d
Study: 18992854
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,800 mg
Study: 3102585
Drug: Verapamil SR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR, 360 mg
Study: 27863979
Drug: ADA fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA fasting glucose concentration cutoff (5.6-6.9 mmol/L)
Study: 27863979
Drug: WHO fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO fasting glucose concentration cutoff (6.1-6.9 mmol/L)
Study: 18354933
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intervention
Study: 18354933
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of intervention
Study: 17161044
Drug: Prehospital fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital fibrinolysis (PHF); administered within 6 hours of symptom onset by ambulance.
Study: 17161044
Drug: Inhospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhospital treatment
Study: 26190132
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review by an experienced hospital pharmacist within the ED
Study: 17395895
Drug: Dronabinol (DRO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (DRO), 7.5 mg, single dose
Study: 9743306
Drug: 5‐fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in four weekly doses
Study: 9743306
Drug: 5‐fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in every‐4‐week dose
Study: 9743306
Drug: 5‐fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2))
Study: 9815951
Drug: Letrozole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.5 mg/day
Study: 2299605
Drug: Daily intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravesical injections of 250 mg of prostaglandin F2 alpha (PGF2 alpha) (n = 23)
Study: 2299605
Drug: Daily 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 10‐mg PGE2 vaginal suppository (n = 22)
Study: 2299605
Drug: Daily saline
Normalized name: SODIUM CHLORIDE 0.9 g in 100 mL NASAL AEROSOL, SPRAY [EQUATE DAILY SALINE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily saline injection to the bladder (control group, n = 24)
Study: 24199747
Drug: Exercise prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescription and devices for monitoring of risk factors with a smartphone data portal equipped with a mobile health application
Study: 21393611
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n = 14)
Study: 21393611
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus plus enalapril and atorvastatin (SRL group)
Study: 21393611
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus atorvastatin (CONTROL group, n = 9)
Study: 21393611
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus atorvastatin (CONTROL group)
Study: 19590473
Drug: 1% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lignocaine injections
Study: 19590473
Drug: N-saline injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-saline injections
Study: 10868865
Drug: Troglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone monotherapy (600 mg daily)
Study: 10868865
Drug: Troglitazone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone with sulfonylurea (600 mg daily)
Study: 10868865
Drug: Troglitazone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone with insulin (600 mg daily)
Study: 10868865
Drug: Troglitazone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (all combinations, 600 mg daily)
Study: 1839798
Drug: 17‐beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐beta estradiol valerianate (E2) (2 mg)
Study: 1839798
Drug: Micronized E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized E2 (2 mg) plus estriol (E3) (1 mg)
Study: 6222901
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 250 mg twice a day
Study: 6222901
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 250 mg
Study: 29138224
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Metformin (E + M)
Study: 22067089
Drug: Intensified Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified Medical therapy
Study: 22067089
Drug: Standard Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical therapy
Study: 20861211
Drug: Coffee mannooligosaccharides
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee mannooligosaccharides (MOS) beverage (4 g/d)
Study: 18227044
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of alanyl-glutamine (Gln) with standard total parenteral nutrition (TPN) for 1 week
Study: 18227044
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control) with standard total parenteral nutrition (TPN) for 1 week
Study: 8560112
Drug: Intravenous Diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Diltiazem (DTZ)
Study: 8560112
Drug: Intravenous Nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Nitroglycerin (NTG)
Study: 2075139
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus pirenzepine (50 mg before bedtime)
Study: 2075139
Drug: Sucralfate (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (4.0 g daily)
Study: 20571386
Drug: Nitroimidazole antibiotics
Normalized name: 2-methyl-5-nitroimidazole-1-ethanol
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitroimidazole antibiotics
Study: 20571386
Drug: Postoperative immunomodulators
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative immunomodulators and antitumor necrosis factor agents
Study: 18615321
Drug: Outreach Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outreach Treatment Program (OTP)
Study: 8677455
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Study: 8677455
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Study: 8677455
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Study: 8677455
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Study: 1990895
Drug: Propofol (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1-3 mg.kg-1 injected over 10-30 s)
Study: 1990895
Drug: Propofol (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1-3 mg.kg-1 injected over 10-30 s) with halothane (1-3%)
Study: 6760217
Drug: Diclofensine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofensine (mean daily dose of 57.5 mg for 3 weeks)
Study: 30991863
Drug: Apatinib mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib mesylate combined with chemotherapy (taxane, irinotecan, and fluorouracil)